NeoStem: Continued Progress and 2014 Catalysts Print E-mail
By Brian Wilson - Lead Contributor   
Wednesday, 18 December 2013 10:32
NeoStem (NASDAQ: NBS) recently announced the completion of the enrollment phase for their Phase II trial. This 160 patient trial will determine the safety and effect the company's most advanced therapy - AMR-001 - on patients with acute myocardial infarction. The recent announcement did not have a noticeable impact on the stock's performance, although it does signify that the company is on track to have the all-important top-line data release for AMR-001 in 2014.

Four 2014 Catalysts to wait for

There are a number of catalysts to look forward to in 2014. Here are four of the most important ones, and our estimates on when they should occur:

* June 2014 - Primary completion of Phase II AMI-001 trial in STEMI

* 3Q 2014 - Phase II data from Phase II AMI-001 trial in STEMI

* 1H 2014 - Phase I results for regulatory T-cell program in diabetes

* 2H 2014 - Initiation of Phase II for regulator T-cell program in diabetes

Of these events, investors may want to pay the most attention to the AMI-001 Phase II data, since we believe this would probably have the most significant impact on share price. The indication being targeted is huge (>220,000 patients per year), and we believe that Neostem would see much more interest after their top cell therapy is validated with Phase II data.

AMR-001

AMR-001 is an autologous cell therapy made up of CD34+ and CXCR4+ cells. It has demonstrated the ability to improve patient perfusion rates in previous clinical trials. After Phase II data is released, we are expecting to see comparable benefit in a much larger patient population. This therapy Is being developed for the treatment of acute myocardial infarction (via the Phase II PreSERVE trial mentioned earlier). It will also be a possible treatment for congestive heart failure (Phase IB/IIA pending), and traumatic brain injury (preclinical).

Developments

NeoStem continues to generate substantial (~$3.7 M/quarter) revenue from its Progenitor Cell Therapy (PCT) division, and many investors see this as a way to support the company’s clinical development programs in cardiovascular disease, autoimmune disorders, and tissue regeneration.

You have been signed out of this account.This may have happened automatically because another user signed in from the same browser. To continue using this account, you will need to sign in again. This is done to protect your account and to ensure the privacy of your information.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter